TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
ATNM

Actinium Pharmaceuticals Inc

Healthcare · Biotechnology

1.20$ +0.8% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ATNM
Line item 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– +1,280.5% -65.5% -4.3% -92.9% +0.0% +3,859,114.7% -0.4% +31.3% +251.3% -15.3% -18.6% -18.8% -21.6% +468.9% +21.1% +42.1% -28.7% -5.6% -32.7%
– +1,280.5% -65.5% -4.3% -92.9% +0.0% +3,857,108.0% -0.6% +28.8% +257.5% -15.4% -20.3% -19.7% -29.6% +543.6% +22.8% +39.1% -29.5% -4.8% -33.7%
– +1,280.5% -65.5% -4.3% -92.9% +0.0% +3,745,679.3% -1.5% +21.2% +282.3% -20.0% -15.2% -21.4% -32.3% +587.4% +22.4% +39.9% -29.6% -4.9% -34.2%
– +1,280.5% -65.5% -4.3% -92.9% +0.0% +3,745,679.3% -1.5% +21.4% +281.7% -20.0% -15.2% -21.4% -32.3% +587.4% +22.4% +39.9% -29.6% -4.9% -34.2%
– – – – – – – – – – – – – – – – – – – –
– – – – – – – +364.0% +817.4% -16.9% -16.5% -35.2% +107.1% +860.9% -9.7% -38.0% +361.3% – – –
– +110.1% +92.2% +29.2% -3.7% -10.9% +5,396.3% +57.8% +29.6% -51.4% -2.0% +3.2% +30.2% -0.8% -15.7% +34.8% +597.2% -5.5% -2.1% -0.5%
– -15.8% +616.5% +13.5% +20.6% -27.0% +17,547.3% +57.8% +29.6% -51.4% -2.0% +3.2% +29.9% -11.9% -10.8% +43.5% +55.4% -20.1% -4.1% -2.2%
– – – – – – +12.6% +12.7% +79.7% -6.3% +13.2% -94.7% +1,466.0% +199.3% -42.8% -28.1% +62.2% +8.6% +7.2% +24.5%
– -32.7% +424.4% +9.2% +1.4% +4,606.5% +39.2% -57.8% +502.7% -35.5% +184.6% +10.9% +25.0% -20.9% -5.6% +27.5% +83.0% -21.5% -4.8% –
– – – – – – – -236.1% – – -18.0% -24.1% -35.5% -36.0% +986.4% +19.9% -9.6% -45.3% -10.0% -76.1%
– – – – – – – – – – – – – – – – – – – –
– +382.9% +0.0% +0.0% +0.0% -92.8% +37.6% +1,961.9% +20.3% +39.5% +27.0% +37.8% +58.9% +40.8% +143.9% +69.5% +17.4% +10.2% +13.0% +3.7%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?